Viridian Therapeutics initiates trial for VRDN-003 in Thyroid Eye Disease
Viridian Therapeutics is conducting a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of VRDN-003 in patients with Thyroid Eye Disease.
Asset / Drug
Drug and asset intelligence for VRDN-003 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.